Institutional shares held 97.2 Million
749K calls
553K puts
Total value of holdings $11.7B
$90.3M calls
$66.7M puts
Market Cap $11.5B
95,639,296 Shares Out.
Institutional ownership 101.6%
# of Institutions 650


Latest Institutional Activity in NBIX

Top Purchases

Q1 2025
Dodge & Cox Shares Held: 5.53M ($667M)
Q1 2025
Wellington Management Group LLP Shares Held: 2.1M ($253M)
Q1 2025
Jpmorgan Chase & CO Shares Held: 2.67M ($322M)
Q1 2025
Deerfield Management Company, L.P. (Series C) Shares Held: 1.49M ($180M)
Q1 2025
Assenagon Asset Management S.A. Shares Held: 393K ($47.4M)

Top Sells

Q1 2025
Citadel Advisors LLC Shares Held: 889K ($107M)
Q1 2025
Aqr Capital Management LLC Shares Held: 1.07M ($130M)
Q1 2025
Los Angeles Capital Management LLC Shares Held: 3.81K ($459K)
Q1 2025
Rock Springs Capital Management LP Shares Held: 279K ($33.6M)
Q1 2025
Invesco Ltd. Shares Held: 567K ($68.4M)

About NBIX

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL ? Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.


Insider Transactions at NBIX

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
474K Shares
From 19 Insiders
Exercise of conversion of derivative security 474K shares
Sell / Disposition
439K Shares
From 15 Insiders
Open market or private sale 437K shares
Bona fide gift 2.19K shares

Track Institutional and Insider Activities on NBIX

Follow NEUROCRINE BIOSCIENCES INC and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells NBIX shares.

Notify only if

Insider Trading

Get notified when an Neurocrine Biosciences Inc insider buys or sells NBIX shares.

Notify only if

News

Receive news related to NEUROCRINE BIOSCIENCES INC

Track Activities on NBIX